| Description | Inarigivir soproxil (SB9200) is an agonist of innate immunity. It also displays effective antiviral activity against resistant hepatitis C virus (HCV) variants (EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems). |
| In vitro | Inarigivir soproxil 能够抑制 HCV 复制，其抑制效果在 1a 和 1b 基因型之间相比较是可比较的。该化合物为口服的先天免疫调节剂，其作用机制被认为是通过激活 RIG-I 和 NOD2 途径实现的。Inarigivir soproxil 展现了对 HCV 的全基因型抗病毒活性，并对 DAA 抗药性 HCV 变体有效。SB 9200 对包括 HCV、诺如病毒、呼吸道合胞病毒及流感病毒在内的 RNA 病毒具有广谱抗病毒活性，并已证明对乙型肝炎病毒（HBV）有效[1]。 |
| Target activity | HCV 1a/1b:(EC50)2.2/1.0 μM |
| Synonyms | SB9200 |
| molecular weight | 703.62 |
| Molecular formula | C25H34N7O13PS |
| CAS | 942123-43-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 102 mg/mL (144.96 mM) |
| References | 1. Jones M, ET AL. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628. |